Rafael Pharmaceuticals reports progress with rare cancer drug
WEBMar 1, 2022 · The pursuit of drugs aimed toward the treatment of rare cancers involves a unique set of challenges. Outsourcing-Pharma recently spoke with Sanjeev Luther, president and CEO of Rafael Pharmaceuticals (which specializes in the development of treatments for rare cancers) about its lead drug CPI-613 (devimistat) and other projects in process, as well as advice on dealing with challenges in the path.
Premier Research: holistic approach benefits development
WEBOct 6, 2020 · Holistic design starts off with designing a target product profile that considers the end goal early in the development planning. Also, part of a successful holistic approach, Sharif suggested, is asking thoughtful, appropriate questions at the outset, making sure to consider outcome-focused impactful issues at every stage of development.
How Clario is improving clinical trials: 'Therapies that hold …
WEBDec 11, 2023 · Dr. Michael O’Neal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.
Top 5 CDMOs hold 15% of the market as industry consolidation is ...
WEBOct 22, 2018 · Today, the top five contract development and manufacturing organizations (CDMOs) collectively account for approximately 15% of the market – valued at $92.3bn (€80.4bn) in 2017 – compared to the contract research organization (CRO) space, where the top five holds 70%, Kevin Bottomley, Results International, named the (likely) top five ...
ICON to acquire PRA Health Sciences in $12b deal
WEBFeb 25, 2021 · ICON, a Dublin-based contract research organization (CRO) has entered into an agreement to acquire PRA Health Sciences, another CRO currently sited in Raleigh, North Carolina. The arrangement comprises a cash and stock transaction valued at approximately $12bn USD. According to company leaders, the transaction stands to benefit pharmaceutical ...
$680M deal with CBC and Mubadala shifts UCB's strategy
WEBAug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company. This deal marks a pivotal moment in UCB’s evolution, as the company shifts its focus towards innovation and ...
Highlight 1 study to test fezolinetant in women with breast cancer
WEBAug 27, 2024 · The Highlight 1 study is a randomized, placebo-controlled, double-blind phase 3 clinical trial designed to evaluate the efficacy and safety of fezolinetant for the treatment of moderate to severe VMS in women with stage 0 to 3 hormone receptor-positive breast cancer receiving adjuvant endocrine therapy. Approximately 540 participants are ...
All news articles for July 26, 2019 - outsourcing-pharma.com
WEBJul 26, 2019 · TransCelerate outlines newest initiatives to advance efficiencies across research ecosystem. 26-Jul-2019 By Melissa Fassbender . TransCelerate BioPharma – and its subsidiary BioCelerate – launch new initiatives aimed at enhancing the research and development ecosystem, progressing its mission of getting innovative therapies to patients faster, says EVP.
NCI and Medidata extend partnership by five years
WEBOct 9, 2023 · NCI and Medidata extend partnership by five years to support critical oncology research. A 15-year partnership between Medidata, a Dassault Systèmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health. This renewed commitment, spanning an additional five years ...
All news - outsourcing-pharma.com
WEBAll news. News and analysis on clinical trial services and contract research and development. Quotient Sciences expands with mRNA Focus at CPHI 2024. During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA regulations. SGD Pharma to showcase new glass packaging solutions at ...